ClinicalTrials.gg

TargetBeta

S1PR1

sphingosine-1-phosphate receptor 1 · also edg-1, D1S3362, CD363, EDG1 · Sphingosine 1-phosphate receptors

5 programs in company-led studies act on S1PR1, from 4 companies: 4 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
fingolimodruleNovartisphase 4554 runningS1PR2, S1PR3, S1PR4, S1PR5NCIt
cenerimodruleViatrisphase 3145 running–ChEMBL
etrasimodrulePfizerphase 3214 runningS1PR4, S1PR5ChEMBL
ponesimodruleJohnson & Johnsonphase 3162 running–NCIt
mocravimodruleNovartisphase 351 runningMBTPS1ChEMBL

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.